Seeking Alpha

Celgene Corporation (CELG)

  • Apr. 5, 2013, 8:13 AM
    Celgene (CELG) gets an upgrade from Deutsche Bank to Buy from Hold. The bank says survey data gathered from 100 dermatologists and rheumatologists suggests Apremilast is a "blockbuster." DB raises its price target from $105 to $143. Shares +1.4% premarket.
  • Apr. 4, 2013, 9:51 AM
    Cyclacel (CYCC -2.8%) sells four patents to Celgene (CELG +0.8%) for a onetime payment of $5.5M, effectively resolving pending litigation between the two companies. Cyclacel is now free to get back to focusing "on the development of [its] pipeline," CEO Spiro Rombotis says.
    | Comment!
  • Mar. 28, 2013, 4:24 PM
    Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 
    | 1 Comment
  • Mar. 11, 2013, 9:34 AM
    The National Comprehensive Cancer Network (NCCN) adds the combination of carfilzomib, which is sold by Onyx Pharmaceuticals (ONXX), lendalidomide (made by Celgene (CELG)) and dexamethasone to its guidelines as an option for treating multiple myeloma patients who are also transplant candidates. The NCCN also adds carfilzomib monotherapy and other agents as a preferred treatment regimen for salvage therapy. The FDA hasn't approved carfilzomib for these uses, so Onyx won't market carfilzomib for them.
    | Comment!
  • Mar. 4, 2013, 9:37 AM
    Celgene (CELG) -2.2% as hopes fade that the company's Apremilast anti-inflammatory treatment can become a blockbuster. At the weekend, Celgene released disappointing results for Apremilast from a Phase III trial of patients with psoriasis, an autoimmune skin disease.
    | Comment!
  • Mar. 3, 2013, 9:02 AM
    Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just 33% of patients had a 75% reduction in psoriasis vs. 41% in the midstage trial. Management had hoped for $1.1B-$1.75B in peak sales for the drug, a figure few on the Street were buying. (PR)
  • Mar. 3, 2013, 4:02 AM
    Celgene's (CELG) Apremilast anti-inflammatory treatment reduced the symptoms of psoriasis, an autoimmune skin disease, by 75% in a third of patients in a Phase III trial. However, that's below the 41% rate in a Phase II study, raising doubts about whether Apremilast will meet Celgene's hopes and become a new blockbuster drug. Apremilast would compete with rival medicines from AbbVie (ABBV) and Amgen (AMGN). (PR)
    | Comment!
  • Feb. 20, 2013, 8:45 AM
    Celgene (CELG +1.8%) agrees to buy back $600M in stock from an investment bank as part of its repurchase program. So far this year, the company has bought back $385M in shares and has $1.45B remaining in the scheme. Celgene has repurchased $5.05B of stock over the past four years.
    | 1 Comment
  • Feb. 11, 2013, 8:38 AM
    The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with relapsed or refractory mantle cell lymphoma (MCL) after prior therapy. Revlimid, in combination with the steroid dexamethasone, has also won approval from China's State Food & Drug Administration for use in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. (PR)
    | Comment!
  • Feb. 8, 2013, 4:30 PM
    The FDA approves Celgene's (CELG) Pomalyst brand therapy for patients with multiple myeloma. The approval is based on response rate; as of yet, clinical benefit, such as improvement in survival or symptoms, has not been verified.
    | Comment!
  • Jan. 24, 2013, 2:23 PM
    Celgene (CELG -1%) slips after posting a lackluster Q4 report, with earnings matching analyst expectations while revenue falls just short of estimates. The company reaffirms its FY13 outlook with revenue just shy of expectations, expecting to earn between $5.50 to $5.60 a share with 11% sales growth on around $6B in sales. The Street is looking for an EPS of $5.64 on $6.1B in revenue.
  • Jan. 24, 2013, 7:33 AM
    Celgene (CELG): Q4 EPS of $1.32 in-line. Revenue of $1.42B (+14% Y/Y) misses by $0.03B. (PR)
    | Comment!
  • Jan. 24, 2013, 12:05 AM
    Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX
    | Comment!
  • Jan. 23, 2013, 5:30 PM
    Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX
    | Comment!
  • Jan. 23, 2013, 2:43 PM
    Threshold Pharmaceuticals (THLD +18%) soars after Celgene (CELG -0.7%) reported positive Phase III data for Abraxane, its prospective treatment for pancreatic cancer, but the data came in slightly below analysts' expectations. Stifel Nicolaus reiterated a Buy on THLD after the news, saying that its own treatment will be more competitive with CELG's product.
    | Comment!
  • Jan. 8, 2013, 8:25 AM
    Celgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a positive forecast yesterday. Jefferies raises its price target to $104 from $94 while Stifel Nicolaus ups its goal to $98 from $89, with both firms maintaining Buy ratings. RBC upgrades Celgene to Outperform from Sector Perform and ups its target to $100 from $90, while Piper Jaffray upgrades the biotech to Overweight from Neutral.
    | Comment!
Visit Seeking Alpha's
CELG vs. ETF Alternatives
Company Description
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States